Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMBIENCE study of zenagamtide versus placebo for cardiovascular risk reduction in adults with established atherosclerotic cardiovascular disease and overweight or obesity
jRCT2031260596Recruiting
- Sponsor
- Novo Nordisk
- Start
- Oct 2026
- Modality
- Small Molecules, Peptides
01
Overview
Randomised trial in atherosclerotic disease, Overweight and obesity comparing Zenagamtide with Placebo (2 arms). Started Oct 2026; status: recruiting.
02
Drugs
amycretin
03
Conditions
atherosclerotic diseaseOverweightobesity
Beyond the preview
Go deeper on jRCT2031260596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260596.